Eiger BioPharmaceuticals, Inc. EIGR
Day range unavailable
52-week range unavailable
- Market cap
- 2.55M
- Revenue (ttm)
- 14.67M
- Shares out
- 1.48M
- Forward P/E
- -0.48
- Beta
- 1.84
- Analysts
- Strong Buy
- Price target
- 30.00 (+1639.1%)
- Earnings date
- May 9, 2024
2Y -26.47 (-93.87%)
Key statistics
- Enterprise value
- 3.88M
- PEG ratio
- 0.00
- Price / sales
- 0.17
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -20.30%
- Free cash flow
- -52.16M
- Total cash
- 44.43M
- Total debt
- 40.94M
- Return on equity
- -225.93%
- Short % of float
- 3.22%
- 50-day average
- 4.59
- 200-day average
- 10.27
Analyst view
Consensus: strong buy
- Strong buy4
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -5.40.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eigerbio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on EIGR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APELIAN DAVID | Director | Sale | Aug 15, 2022 | 11,000 |
| CORY DAVID A | Chief Executive Officer | Stock Award(Grant) | Mar 10, 2022 | 169,183 |
| DIETZ THOMAS JOHN | Director | Purchase | Jan 22, 2023 | 0 |
| GLENN JEFFREY SCOTT | Director | Purchase | Dec 21, 2022 | 338,879 |
| KAWAS LEEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 30, 2023 | 0 |
| KAYNE RICHARD ALAN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 1, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ameriprise Financial, Inc. | 16.90% | 250,182 | 431.56K | Dec 30, 2023 |
| Propel Bio Management, LLC | 9.89% | 146,380 | 252.50K | Dec 30, 2023 |
| 683 Capital Management LLC | 4.73% | 69,999 | 120.75K | Dec 30, 2023 |
| Vanguard Group Inc | 4.10% | 60,691 | 104.69K | Dec 30, 2023 |
| Blackrock Inc. | 1.31% | 19,457 | 33.56K | Dec 30, 2023 |
| Geode Capital Management, LLC | 0.85% | 12,657 | 21.83K | Dec 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 6.08% | 89,999 | 155.25K | Dec 30, 2023 |
| Columbia Fds Ser Tr II-Columbia Seligman Technology & Information Fund | 5.22% | 77,304 | 133.35K | Nov 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.80% | 41,482 | 71.56K | Dec 30, 2023 |
| Columbia Funds Ser Tr II-Columbia Seligman Global Technology Fund | 2.39% | 35,332 | 60.95K | Jan 30, 2024 |
| Vanguard Extended Market Index Fund | 1.22% | 18,024 | 31.09K | Dec 30, 2023 |
| Fidelity Extended Market Index Fund | 0.46% | 6,756 | 11.65K | Feb 28, 2024 |